FCM
DNLI icon

Frontier Capital Management’s Denali Therapeutics DNLI Stock Holding History

Frontier Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,742
Closed -$442K – 290
2021
Q1 		$442K Sell
7,742
-70,191
-90% -$4.7M ﹤0.01% 270
2020
Q4 		$6.53M Sell
77,933
-13,022
-14% -$787K 0.05% 248
2020
Q3 		$3.26M Buy
+90,955
New +$2.74M 0.03% 274

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Frontier Capital Management's DNLI Position: Q2 2021 in Review

Frontier Capital Management sold out of Denali Therapeutics (DNLI) in Q2 2021, closing a stake of 7,742 shares — an estimated $442K sold.

Frontier Capital Management first reported a position in DNLI in Q3 2020 and held it in 3 quarters. The position peaked at $6.53M in Q4 2020. 210 funds tracked by Wall St. Rank hold DNLI as of Q2 2021.

  • Frontier Capital Management reported no remaining Denali Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Frontier Capital Management sold 7,742 Denali Therapeutics shares in Q2 2021, an estimated $442K.
  • Frontier Capital Management first reported a position in Denali Therapeutics in Q3 2020 and held it in 3 quarters.
  • Frontier Capital Management's Denali Therapeutics position peaked at $6.53M in Q4 2020.
  • 210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2021.

Based on Frontier Capital Management's 13F filing for Q2 2021, filed 9 Aug 2021.